[Extracorporeal shockwave therapy in symptomatic heel spurs. An overview]

Orthopade. 2002 Jul;31(7):637-44. doi: 10.1007/s00132-002-0323-z.
[Article in German]


Extracorporeal shock wave application (ESWA) has been successfully used for years in routine clinical management of plantar fasciitis. So far no clinical trails have shown the efficiency in placebo-controlled protocols. This paper presents an overview of conservative and operative treatment modalities with respect to their efficacy. Results of a prospective randomized placebo-controlled double-blind multicenter trial to show efficiency and safety of ESWT are presented. In patients treated conservatively without success, a single shock wave application can improve the condition significantly compared with placebo treatment (p = 0.0149). The Roles and Maudsley score also showed a significant improvement between the groups, with 61.6% good or excellent results in the verum group and 39.7% in the placebo group (p = 0.0128). Therapy-related side effects (local swelling, petechia) are rare. The data presented in this study led to FDA approval in January 2002 of the shock wave device used.

Publication types

  • Clinical Trial
  • Evaluation Study
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Double-Blind Method
  • Fasciitis, Plantar / therapy*
  • Female
  • Heel Spur / therapy*
  • Humans
  • Lithotripsy*
  • Male
  • Middle Aged
  • Pain Measurement
  • Treatment Outcome